Bayer Sees Pharma Growth as Unit Chief Touts Comeback Story

Bayer AG’s pharmaceuticals unit is on track for a return to growth as new drugs for cancer and kidney disease offset sales lost to patent expirations.

“Bayer is truly turning a corner,” Stefan Oelrich, who heads the German company’s pharma business, said in an interview at the JPMorgan Healthcare Conference in San Francisco. “This is a real comeback story.”